An interventional study of Creatine Monohdyrate in Post-partum and Women, sponsored by University of North Carolina, Chapel Hill. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-08-31.
Sponsored by University of North Carolina, Chapel Hill · Not applicable, Interventional, and Other
Among 35 studies in Motor Activity by University of North Carolina, Chapel Hill — 4 open to participants now, 4 under way, none of them phase 3. Motor Activity · University of North Carolina, Chapel Hill.
Among the 35 studies in Motor Activity by University of North Carolina, Chapel Hill, this one is the 28th largest by planned enrollment, is one of 2 that started in 2026, is one of 34 with no phase, and was the 35th registered.
9,798 studies on the registry are indexed under Motor Activity; 1,910 are open to participants now.
This study's planned enrollment of 40 is below the median of 60 across 8,388 interventional studies indexed under Motor Activity.
Browse Motor Activity studies →4 of the 35 studies in Motor Activity by University of North Carolina, Chapel Hill are open now, in 1 country. Each count lists the studies.
Of the 1,201 Motor Activity studies recruiting now, 517 (43%) set no upper age limit and 535 (45%) stop at 75 or younger; 180 take children under 18; 420 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →35 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2026.
Median enrollment 78 across the 35 interventional studies. Of the 31 that completed or were terminated, 8 (26%) have results posted.
University of North Carolina, Chapel Hill is the lead sponsor of 1,372 studies on the registry; 133 are open to participants now.
Of its 161 completed or terminated interventional studies of FDA-regulated products, 139 (86%) have results posted.
2 of the studies in Motor Activity by University of North Carolina, Chapel Hill that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07699302University of North Carolina, Chapel HillClearance in Primary Ciliary Dyskinesia | 2027-01 |
| NCT07795853University of North Carolina, Chapel HillCreatine for Recovery and Thinking in Mothers | 2027-05-10 |
Among the 35 studies in Motor Activity by University of North Carolina, Chapel Hill, from their registry updates:
Nothing recorded among them since 2026-09-25.
The purpose of this randomized, double-blind, parallel-group trial is to compare the effects of two doses of creatine monohydrate (5 g/day versus 10 g/day) administered for four weeks in postpartum women. The study will evaluate exercise performance, post-exercise recovery, cognitive function, and brain creatine concentrations in a sub-sample.
Postpartum women frequently experience changes in physical performance, recovery, cognition, sleep quality, and mood. Creatine supplementation may enhance energy availability in skeletal muscle and brain tissue, potentially improving exercise performance, recovery, and cognitive function. This study will enroll 40 postpartum women and randomly assign participants in a 1:1 ratio to receive either 5 g/day or 10 g/day of creatine monohydrate for four weeks in a double-blind fashion. Assessments will be conducted before and after supplementation and will include repeated sprint ability testing, skeletal muscle oxygen recovery, and cognitive testing. A subsample of 20 participants will undergo magnetic resonance spectroscopy to assess brain creatine stores.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants consume 5 grams per day of creatine monohydrate for 28 consecutive days.
Dietary Supplement: Creatine Monohdyrate
Participants consume 10 grams per day of creatine monohydrate for 28 consecutive days.
Dietary Supplement: Creatine Monohdyrate
Creatine monohydrate taken daily mixed with 6-8 oz of water.
Repeated Sprint Ability Peak Power
Peak power (Watts) measured during a repeated sprint ability cycling test.
Time frame: Change from baseline to 4 weeks post-supplementation.
Fatigue Index
Fatigue index (%) calculated from repeated sprint ability testing.
Time frame: Change from baseline to 4 weeks post-supplementation.
Skeletal Muscle Oxygen Recovery
Recovery rate constant of skeletal muscle oxygen consumption following exercise measured by near-infrared spectroscopy and arterial occlusion procedures.
Time frame: Change from baseline to 4 weeks post-supplementation
Executive Function
Executive function measured using the NIH Toolbox Flanker Inhibitory Control and Attention Test.
Time frame: Change from baseline to 4 weeks post-supplementation
Working Memory
Working memory measured using the NIH Toolbox List Sorting Working Memory Test.
Time frame: Change in baseline to 4 weeks post-supplementation.
Brain Creatine Concentration
Brain phosphocreatine and related bioenergetic metabolites assessed using phosphorus magnetic resonance spectroscopy (³¹P-MRS) in the imaging subsample
Time frame: Change from baseline to 4 weeks post-supplementation
Plan to share: Yes — Deidentified individual participant data that support the results reported in publications arising from this study will be shared beginning 9 to 36 months following publication, provided that the investigator requesting the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with the University of North Carolina (UNC) at Chapel Hill. When data sharing is permitted, a Data Use Agreement specifying the permitted uses of the shared data must be fully executed before any data are released.
Supporting information: Study protocol
Time frame: Data will be available beginning 9 to 36 months following publication of the primary study results and will remain available for a period determined by UNC data-sharing policies and the terms of the applicable Data Use Agreement.
Access criteria: Investigators seeking access to the data must provide documentation of IRB, IEC, or REB approval, where applicable, and enter into a fully executed Data Use Agreement with the University of North Carolina at Chapel Hill prior to receipt of data. Requests will be reviewed by the study investigator and the University in accordance with institutional policies.
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for May 2027, 8 months later.
Of 5,147 non-industry interventional studies with no phase under Motor Activity, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 8 months is below that.
Counting every sponsor, half of 5,207 studies reached it within 17 months; a quarter within 7 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of North Carolina, Chapel Hill →